Search for European Projects

Over 40 European Projects Found

Searched on 125080 European Projects

 ONGOING 

European Human Biomonitoring Initiative (HBM4EU)

Start date: Jan 1, 2017, End date: Dec 31, 2021,

The overarching goal of the European Human Biomonitoring Initiative (HBM4EU) is to generate knowledge to inform the safe management of chemicals and so protect human health. We will use human biomonitoring to understand human exposure to chemicals and resulting health impacts and will communicate with policy makers to ensure that our results are exploited in the design of new chemicals policies an ...
Read Project

 43

 ONGOING 
The vision of EU-ToxRisk is to drive a paradigm shift in toxicology towards an animal-free, mechanism-based integrated approach to chemical safety assessment. The project will unite all relevant disciplines and stakeholders to establish: i) pragmatic, solid read-across procedures incorporating mechanistic and toxicokinetic knowledge; and ii) ab initio hazard and risk assessment strategies of chemi ...
Read Project

 43

 ONGOING 

EURopean Endeavour for Chimeric Antigen Receptor Therapies (EURE-CART)

Start date: Jan 1, 2017, End date: Dec 31, 2020,

Cancer is rapidly becoming the most frequent cause of death in EU. Though enormously expensive (several billions EUR/year), currently available anti-cancer therapies are major causes of chronic diseases. Adoptive immunotherapy with T cells genetically modified with a tumour-reactive chimeric antigen receptor (CAR) is an innovative therapeutic concept, promising to eradicate cancer without causing ...
Read Project

 11

 ONGOING 
Many HIV vaccine concepts and several efficacy trials have been conducted in the prophylactic and therapeutic fields with limited success. There is an urgent need to develop better vaccines and tools predictive of immunogenicity and of correlates of protection at early stage of vaccine development to mitigate the risks of failure. To address these complex and challenging scientific issues, the Eur ...
Read Project

 43

 ONGOING 
The goal of this multidisciplinary project is to comprehensively characterise high-grade serous ovarian cancer (HGS-OvCa) at single-cell level, identify the best combination of drug combination to kill HGS-OvCa populations and commercialise a predictive biomarker kit for finding the right therapeutic regimen to the right patient.This project takes an advantage on prospectively and longitudinally ...
Read Project

 9

 ONGOING 

European AIDS Vaccine Initiative 2020 (EAVI2020)

Start date: Nov 1, 2015, End date: Oct 31, 2020,

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradicati ...
Read Project

 27

 ONGOING 
The BlueHealth Consortium brings together a multi-disciplinary team of experts reaching across all 28 European Union countries. The proposed 4.5 year BlueHealth Project takes an international, interdisciplinary and multi-sector approach to health promotion and disease prevention by investigating the relationship between the EU’s ‘blue infrastructure’ and the health and well-being of its citizens. ...
Read Project

 13

 ONGOING 
The proposed European Concerted Programme on Radiation Protection Research (acronym: CONCERT) aims to contribute to the sustainable integration of European and national research programmes in radiation protection. It will do so by focusing resources and efforts in five key directions:• Bring together the elements of the European scientific communities in the fields of radiation effects and risks, ...
Read Project

 36

 ONGOING 
Healthspan (the life period when one is generally healthy and free from serious disease) depends on nature (genetic make-up) and nurture (environmental influences, from the earliest stages of development throughout life). Genetic studies increasingly reveal mutations and polymorphisms that may affect healthspan. Similarly, claims abound about lifestyle modifications or treatments improving healths ...
Read Project

 20

 ONGOING 
Background: Influenza viruses cause annual epidemic and occasional pandemics, both of which induce significant morbidity and mortality. Influenza infections affect all age groups but children and adults over the age of 65 are at most risk of developing severe disease.Vaccination is the most effective approach to reduce the impact of annual influenza outbreaks and potential pandemics, however, the ...
Read Project

 26

 ONGOING 
INTCATCH will instigate a paradigm shift in the monitoring and management of surface water quality that is fit for global waters in the period 2020-2050. INTCATCH will do this by developing efficient, user-friendly water monitoring strategies and systems based on innovative technologies that will provide real time data for important parameters, moving towards SMART Rivers. The business model will ...
Read Project

 23

 ONGOING 
Cancer is a worldwide health burden and represents a major public health challenge in Europe. It is responsible for 25% of all deaths, being the second most common cause of death after cardio-vascular diseases and the main cause of mortality among people aged 45–64. Today, an estimated 9 million individuals in Europe live with cancer (Globocan 2008, http://globocan.iarc.fr/). Cancer became a chron ...
Read Project

 30

 ONGOING 
In order to strengthen the sustainability and resilience of health services and systems a unique consortium of governmental and funding organizations plus research institutes, has expressed the ambition to systematically learn from the organisation of care in other settings. Overall objective of TO-REACH is to provide groundwork for an ERA-NET that will contribute to the resilience, effectiveness, ...
Read Project

 31

 ONGOING 
COMPARE aims to harness the rapid advances in molecular technology to improve identification and mitigation of emerging infectious diseases and foodborne outbreaks. To this purpose COMPARE will establish a “One serves all” analytical framework and data exchange platform that will allow real time analysis and interpretation of sequence-based pathogen data in combination with associated data (e.g. c ...
Read Project

 32

 ONGOING 

ERA-NET rare disease research implementing IRDiRC objectives (E-Rare-3)

Start date: Dec 1, 2014, End date: Nov 30, 2019,

Rare diseases (RD) are diseases that affect not more than 5 per 10 000 persons (according to the EU definition). 7000 distinct rare diseases exist, affecting between 6% and 8% of the population (about 30 million EU citizens). The lack of specific health policies for rare diseases and the scarcity of the expertise, translate into delayed diagnosis, few medicinal products and difficult access to car ...
Read Project

 27

 ONGOING 

The Cyanobacteria Blooms Public Information Service (CyanoLakes)

Start date: Nov 1, 2016, End date: Oct 31, 2019,

CyanoLakes will be a global service for the environmental authorities and commercial sector, concerned by health risks and quality of water resources. The proposed project will deliver a fully automated application for assessing toxin producing cyanobacteria blooms in water resources globally, using ground-breaking Copernicus Earth Observation technology. The service foresees a dual dissemination ...
Read Project

 8

 FINISHED 
Conduct Disorder (CD) is the key paediatric disorder characterized by severe aggression. It is heterogeneous, and our understanding of the neurobiology to subtype aggression is limited. MATRICS is a multidisciplinary consortium of academic partners and SMEs that focuses on the subtyping of aggression both within CD and of the broader cross-disorder trait of aggression. MATRICS will test the hypoth ...
Read Project

 21

 FINISHED 

Integrated view on disruptions of early brain development (BRAINVIEW)

Start date: Jan 1, 2015, End date: Dec 31, 2018,

Early onset neurodevelopmental disorders such as autism spectrum disorders (ASD) and attention-deficit hyperactivity disorder (ADHD) are rather common, and affect more than 30 million children in Europe. The disorders carry a huge burden to the patients and their families and to society in general. This burden is linked to their chronic course and the absence of curative treatments. These neurodev ...
Read Project

 12

 FINISHED 
The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Read Project

 49

 FINISHED 
Background Bisphenol A (BPA) and di-2-ethylhexyl phthalate (DEHP) are two environmental endocrine disruptors (EDs) which – despite being non-persistent chemicals - are regularly detected in the environment, in food and, as a consequence, in humans. This is due to their continuous release from manufacturing or processing facilities, despite restrictions ...
Read Project

 3

 FINISHED 
The I-MOVE+ Consortium includes European Union (EU) Public Health Institutes, SME and Universities. It aims at measuring and comparing the effectiveness (VE) and impact (VI) of influenza and Pneumococcal vaccines and vaccination strategies a in the elderly population in Europe. The goal is to develop a sustainable platform of primary care practices, hospitals and laboratory networks that share val ...
Read Project

 33

 FINISHED 
Despite examples of excellent practice, rare disease (RD) research is still mainly fragmented by data and disease types. Individual efforts have little interoperability and almost no systematic connection between detailed clinical and genetic information, biomaterial availability or research/trial datasets. By developing robust mechanisms and standards for linking and exploiting these data, RD-Con ...
Read Project

 30

 FINISHED 
The World Health Organisation in its report on Neglected Tropical Diseases has stated that there is overwhelming evidence to show that the burden caused by many of the 17 diseases that affect more than 1billion people worldwide can be effectively controlled and, in many cases, eliminated or even eradicated. Leishmaniasis caused by Leishmania spp is one of them and poses a grave health risk to an e ...
Read Project

 9

 FINISHED 

Well-School-Tech

Start date: Oct 1, 2016, End date: Sep 30, 2018,

Adolescence and pre-adolescence are crucial moments for the promotion of mental health and the prevention of mental disorders, taking into account that up 50% of common mental disorders have their onset in adolescence, around 14 years of age. The World Health Organization (WHO) estimated that, worldwide, up to 20% of children and adolescents suffer from a problem of emotional development or behavi ...
Read Project

 6

 FINISHED 
Human cystic echinococcosis (CE), one of the most widespread helminthic zoonoses, is a chronic disease caused by infection with the larval stage of the tapeworm Echinococcus granulosus. This disease is highly endemic in some southern (Spain and Italy), eastern (Bulgaria and Romania) European countries and associated (Turkey) countries, where it still represents a major health and economic problem. ...
Read Project

 10

 FINISHED 
Assessing individual exposure to environmental stressors and predicting health outcomes implies that both environmental exposures and epi/genetic variations are reliably measured simultaneously. HEALS (Health and Environment-wide Associations based on Large population Surveys) brings together in an innovative approach a comprehensive array of novel technologies, data analysis and modeling tools th ...
Read Project

 37

 FINISHED 
One of the greatest challenges facing regulators in the ever changing landscape of novel nano-materials is how to design and implement a regulatory process which is robust enough to deal with a rapidly diversifying system of manufactured nanomaterials (MNM) over time. Not only does the complexity of the MNM present a problem for regulators, the validity of data decreases with time, so that the wel ...
Read Project

 46

 FINISHED 

Human Brain Project Specific Grant Agreement 1 (HBP SGA1)

Start date: Apr 1, 2016, End date: Mar 31, 2018,

Understanding the human brain is one of the greatest scientific challenges of our time. Such an understanding can provide profound insights into our humanity, leading to fundamentally new computing technologies, and transforming the diagnosis and treatment of brain disorders. Modern ICT brings this prospect within reach. The HBP Flagship Initiative (HBP) thus proposes a unique strategy that uses I ...
Read Project

 126

 FINISHED 
ECRIN is a distributed ESFRI-roadmap pan-European infrastructure designed to support multinational clinical research, making Europe a single area for clinical studies, taking advantage of its population size to access patients. Servicing multinational trials started during its preparatory phase, and it now applies for an ERIC status by 2011. The ERIC budget will be restricted to core activities re ...
Read Project

 48

 FINISHED 
FRESHER brings together ten research groups, including leaders in the management of large European Foresight projects and highly experienced health policy modelers, in an interdisciplinary team engaged in FoResight and Modelling for European Health policy and Regulation. The overall project objective is the representation of alternative futures where the detection of emerging health scenarios will ...
Read Project

 14

 FINISHED 
ASSET (Action plan in Science in Society in Epidemics and Total pandemics) is a 48 month Mobilisation and Mutual Learning Action Plan (MMLAP), which aims to 1) forge a partnership with complementary perspectives, knowledge and experiences to address effectively scientific and societal challenges raised by pandemics and associated crisis management; 2) explore and map SiS-related issues in global ...
Read Project

 16

 FINISHED 

Bacteria for Cancer Therapy (BaCTher)

Start date: Nov 1, 2015, End date: Oct 31, 2017,

... haracterize the mechanism of STMΔznuABC antitumor activity;3) validate the results obtained in the preliminary studies using alternative in vivo models. The Experienced Researcher (ER), from the Istituto Superiore di Sanità (ISS), Italy, will spend one year at the Cancer Immunobiology Section of the Cancer and Inflammation Program (CIP), Center for Cancer Research (CCR), division of the National C ...
Read Project

 2

 FINISHED 

Advanced Immunization Technologies (ADITEC)

Start date: Oct 1, 2011, End date: Sep 30, 2017,

Vaccines so far have been developed mostly by following an empiric approach. To prevent and possibly cure unresolved and emerging infectious diseases we need to fully exploit the potential of the human immune system. Progress in science and technology makes it possible to achieve what was previously deemed impossible. The scope of this project is to produce knowledge necessary to develop novel and ...
Read Project

 53

 FINISHED 

European Multicentre Tics in Children Studies (EMTICS)

Start date: Dec 1, 2011, End date: May 31, 2017,

This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorder ...
Read Project

 33

 FINISHED 

Open Project for the European Radiation Research Area (OPERRA)

Start date: Jun 1, 2013, End date: May 31, 2017,

"Within the OPERRA project, it is proposed that the MELODI Association, as a well-advanced network, takes the lead in establishing the necessary structures able to manage the long-term European research programmes in radiation protection, also taking advantage of the valuable experience gathered through the DoReMi network of excellence. Whilst in fields adjacent to low-dose risk research (radioeco ...
Read Project

 71

 FINISHED 
The innovative and economic potential of Manufactured Nano Materials (MNMs) is threatened by a limited understanding of the related EHS issues. While toxicity data is continuously becoming available, the relevance to regulators is often unclear or unproven. The shrinking time to market of new MNM drives the need for urgent action by regulators. NANoREG is the first FP7 project to deliver the answe ...
Read Project

 73

 FINISHED 

Promoting the Implementation of Safe by Design (PROSAFE)

Start date: Feb 1, 2015, End date: Jan 31, 2017,

The CSA links different initiatives and facilitates the integration of results from these initiatives, so that a maximum use of these results can benefit the regulatory process. The CSA is designed to facilitate this process and show European leadership on chemical safety, including nano’s. The aim of this activity is to coordinate and support for risk assessment, management and governance by stre ...
Read Project

 17

 FINISHED 

Cross-Mediterranean Environment and Health Network (CROME- LIFE)

Start date: Jul 1, 2013, End date: Dec 31, 2016,

Background Public health indicators are regularly collected in EU Member States but they are hardly ever connected to the environmental condition of individuals. A major limiting factor in most environmental health studies to date has been the uncertainty in quantitative estimates of chronic exposure. Objectives ...
Read Project

 4

 FINISHED 
Research with animals is considered necessary to obtain certain vital knowledge for advancing health research and innovation, but the harm such research may cause animals is ethically problematic. The European legislation regulating animal experimentation is based on the need to balance the two important interests at stake: advancing research and protecting animal welfare. The public sensitivity o ...
Read Project

 6

 FINISHED 
RARE-Bestpractices will develop a sustainable networking platform, supporting the collection of standardized and validated data and efficient exchange of knowledge and reliable information on rare diseases (RD).RD are characterized by low prevalence (EU – 5:10000 persons). There are more than 5000, overall affecting about 30 million citizens of all ages in the EU. RD are often life-threatening and ...
Read Project

 16